Early trial of lenalidomide after transplant for myeloma stopped early
NCT ID NCT01421927
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 1 trial tested the safety of the drug lenalidomide as maintenance therapy after a reduced-intensity stem cell transplant for multiple myeloma. Only 13 people took part, and the study was terminated early. The goal was to see if lenalidomide could help prevent the cancer from coming back without causing too many side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
lenalidomide
What this could lead to
If successful, this could point toward a way to lower the chance of cancer returning after a stem cell transplant for multiple myeloma.
What could go wrong
This was a very small, early-phase trial that was terminated early, so results are limited. Lenalidomide can cause serious side effects like low blood counts and graft-versus-host disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU Bordeaux - Hôpital Haut-Lévêque
Pessac, 33600, France